On March 14, 2022 KIYATEC, the leader in clinically correlated, published functional precision oncology technology reported that six abstracts were accepted for poster presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022 (Press release, KIYATEC, MAR 14, 2022, View Source [SID1234610054]). The meeting will be held in New Orleans from April 8 – 13, 2022 .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

KIYATEC’s clinical and pre-clinical technology platforms, 3D PredictTM and KIYA-PREDICTTM, respectively, are leading the functional precision oncology space with published evidence of predictive response correlated to clinical outcomes. The six abstracts accepted for presentation at the conference include applications in multiple tumor types, immunotherapy drug response, and ex vivo application of PDX for pre-clinical drug development. These works feature collaborations with investigators from XenoSTART and the Adenoid Cystic Carcinoma Research Foundation.

"We are proud to showcase our research at the upcoming AACR (Free AACR Whitepaper) conference," said Tessa DesRochers, Ph.D., Chief Scientific Officer at KIYATEC. "The collection of abstracts demonstrates our dedication to leading with evidence. Our strong data demonstrates that our approach works."

Session titles and information for the abstracts are listed below and are also available on the AACR (Free AACR Whitepaper) online itinerary planner. KIYATEC will exhibit at AACR (Free AACR Whitepaper) at Booth #1449.

KIYATEC presentation schedule:

Ex vivo 3D drug response profiling of XPDX-derived tumor cells for acceleration of preclinical drug development
3D models and Microfluidics, Section 9
April 10th 1:30 – 5 PM

Ex vivo 3D culture of adenoid cystic carcinoma PDX models recapitulate disease biomarkers and predict drug response
3D models and Microfluidics, Section 9
April 10th 1:30 – 5 PM

Engineered 3D tissues facilitate preclinical immunotherapy studies in fully human platforms
Tissue Recombinant, Organ slide, and Decellularized Models, Section 14
April 10th 1:30 – 5 PM

3D PredictTM, an analytically and clinically validated platform for evidence-based functional precision medicine
Biomarkers Predictive of Therapeutic Benefit, Section 31
April 12th 9 AM – 12:30 PM

Organoids standardized to a clinically validated drugs response assay for truly predictive in vitro drug response profiling
Organoid-based models, Section 9
April 12th 1:30 – 5 PM

Dissecting personalized PD-1 inhibitor efficacy using patient-derived 3D spheroids
Vaccines/Immunomodulatory Agents and Interventions, Section 34
April 13th 9 AM – 12:30 PM